FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

How Much Would You Pay for an Old Drug? If You Have MS, a Fortune



























Chart of how much each of the MS drugs in the study cost when they hit the market and how much they cost in 2013

Imagine Apple's first iPhone is still on sale today. Now imagine it costs many times its original price of $599, and that the price goes up every time a new, competing phone is released.

That bizarro world is what the market for multiple sclerosis drugs looks like, as described in a new paper in the journal Neurology. And doctors are calling for it to change.

MS is a chronic disorder of the nervous system that afflicts about 400,000 Americans with a variety of symptoms, including fatigue, difficulty moving, and vision problems. When the first therapies to treat MS were approved in the 1990s, they cost $8,000 to $12,000 a year. Subsequent drugs entered the market with higher prices. The competition didn't drive down cost, as Economics 101 would predict. Instead, the prices of the older drugs increased and rose several times faster than the overall rate at which drug costs increased.

Now all the MS drugs cost between $50,000 and $65,000 a year, including the ones that went for less than $10,000 when they made their debut. "Our data suggest prices of existing [therapies] paradoxically rise, quickly matching prices set by the newest competitor," the authors, from Oregon State University and Oregon Health & Science University, write. (The paper left out the two most recent MS therapies because data weren't available. It also excluded one older drug that's rarely prescribed for MS because of safety concerns.)

A lot of the recent discussion about drug prices in the U.S. has been about expensive new therapies for the liver disease hepatitis C. Those pills are highly effective, curing most patients after a course of a few months, and manufacturers have argued that the high prices are justified, especially if they avoid more costly treatments, such as liver transplants, later on.

There is no cure for MS, though, and patients typically take medication for years or decades. The changes in price for older drugs matter because those drugs are often widely prescribed. Copaxone, approved in 1996, is still the bestselling MS therapy, with 2014 retail sales of $3.4 billion in the U.S., according to data from Bloomberg Intelligence.

The new analysis in Neurology is based on the drugs' average wholesale prices—essentially the list price. Health plans typically negotiate discounts off that price. "Nobody’s paying the list price," said Robert Zirkelbach, spokesman for the drug industry group Pharmaceutical Research & Manufacturers of America, who had not seen the study. "As you have more players in the marketplace, insurers and pharmacy benefit managers are able to negotiate even steeper discounts."

Other data supports the Oregon researchers' analysis. The three MS drugs approved in the 1990s—Bayer's Betaseron, Biogen's Avonex, and Teva's Copaxone—had total U.S. sales of $2 billion in 2006, according to Bloomberg Intelligence data that track what pharmacies pay wholesalers. That figure tripled to more than $6 billion by 2014, even as several competing therapies were approved.

Story Source: The above story is based on materials provided by BLOOMBERG
Note: Materials may be edited for content and length
Click here to read original article


Go to Newer News Go to Older News